Communiqués Clinuvel Pharmaceuticals Limited Deutsche Boerse AG

Actions

Marché Fermé - Deutsche Boerse AG Autres places de cotation 14:38:09 07/06/2024			Varia. 5j.	Varia. 1 janv.
9,1 ^EUR	-0,44 %		-5,41 %	-8,30 %

23/05	Clinuvel Pharmaceuticals s'associe à Valentech Pharma pour introduire un médicament contre la PPE en Amérique latine	MT
14/03	Clinuvel Pharmaceuticals lance un programme de rachat d'actions	MT

Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors	28/03	AQ
Malibu shines a light on CLINUVEL’s pioneering work in photomedicine	05/03	AQ
CLINUVEL Launches CYACÊLLE, Next Generation Solar Care	01/03/23	AQ
Global SCENESSE® demand drives increased CLINUVEL revenues, earnings	24/02/23	AQ
CLINUVEL Drug Significantly Reduces Critical UV Skin Damage in Fair-Skinned Individuals	02/02/23	AQ
CLINUVEL Trial Results Show Drug Reduces DNA Damage	16/01/23	AQ
Clinuvel Pharmaceuticals : Appendix 4C & Activity Report	25/07/22	PU
Clinuvel Pharmaceuticals : Change of Director’s Interest Notice	23/06/22	PU
Clinuvel Pharmaceuticals : Change of Director’s Interest Notice	14/06/22	PU
Clinuvel Pharmaceuticals : H.C. Wainwright Global Investment Conference Presentation	26/05/22	PU
Clinuvel Pharmaceuticals : H.C. Wainwright Global Investment Conference 2022	26/05/22	PU
Clinuvel Pharmaceuticals : Notice of change of interests of initial substantial holder	25/05/22	PU
Clinuvel Pharmaceuticals : Notice of initial substantial holder	20/05/22	PU
CLINUVEL progresses vitiligo treatment program	10/05/22	AQ
Positive final results in stroke	04/05/22	AQ
Letter to shareholders from CLINUVEL’s CEO	29/04/22	AQ
Clinuvel Pharmaceuticals : CEO letter	29/04/22	PU
Clinuvel Pharmaceuticals : Quarterly Activities/Appendix 4C Cash Flow Report	28/04/22	PU
Clinuvel Pharmaceuticals : Appendix 4C & Activity Report	28/04/22	PU
Clinuvel Pharmaceuticals : Notice of ceasing to be a substantial holder	27/04/22	PU

Aucun résultat pour cette recherche